{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:47:01Z","timestamp":1791895621978,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Multiple myeloma (MM) is a deadly plasma cell malignancy with elusive pathogenesis. N6-methyladenosine (m6A) is critically engaged in hematological malignancies. The function of KIAA1429, the largest component of methyltransferases, is unknown. This study delved into the mechanism of KIAA1429 in MM, hoping to offer novel targets for MM therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Bone marrow samples were attained from 55 MM patients and 15 controls. KIAA1429, YTHDF1, and FOXM1 mRNA levels were detected and their correlation was analyzed. Cell viability, proliferation, cell cycle, and apoptosis were testified. Glycolysis-enhancing genes (HK2, ENO1, and\u00a0LDHA), lactate production, and glucose uptake were evaluated. The interaction between FOXM1 mRNA and YTHDF1, m6A-modified FOXM1 level, and FOXM1 stability were assayed. A transplantation tumor model was built to confirm the mechanism of KIAA1429.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>KIAA1429 was at high levels in MM patients and MM cells and linked to poor prognoses. KIAA1429 knockdown restrained MM cell viability, and\u00a0proliferation, arrested G0\/G1 phase, and increased apoptosis. KIAA1429 mRNA in plasma cells from MM patients\u00a0was positively linked with\u00a0to glycolysis-enhancing genes. The levels of glycolysis-enhancing genes, glucose uptake, and lactate production were repressed after KIAA1429 knockdown, along with reduced FOXM1 levels and stability. YTHDF1 recognized KIAA1429-methylated FOXM1 mRNA and raised FOXM1 stability. Knockdown of YTHDF1 curbed aerobic glycolysis and malignant behaviors in MM cells, which was nullified by FOXM1 overexpression. KIAA1429 knockdown also inhibited tumor growth in animal experiments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>KIAA1429 knockdown reduces FOXM1 expression through YTHDF1-mediated m6A modification, thus inhibiting MM aerobic glycolysis and tumorigenesis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                <jats:p>KIAA1429 knockdown reduces FOXM1 expression through YTHDF1-mediated m6A modification, thus inhibiting aerobic glycolysis and tumorigenesis in MM<\/jats:p>\n                \n              <\/jats:sec>","DOI":"10.1007\/s10565-024-09904-2","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:02:04Z","timestamp":1722038524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["KIAA1429 increases FOXM1 expression through YTHDF1\u2013mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma"],"prefix":"10.1007","volume":"40","author":[{"given":"Yue","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youzhi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"9904_CR1","doi-asserted-by":"publisher","unstructured":"Che, F., Ye, X., Wang, Y., Wang, X., Ma, S., Tan, Y., . . . Luo, Z. (2023). METTL3 facilitates multiple myeloma tumorigenesis by enhancing YY1 stability and pri-microRNA-27 maturation in m(6)A-dependent manner. Cell Biol Toxicol, 39(5), 2033\u20132050. https:\/\/doi.org\/10.1007\/s10565-021-09690-1","DOI":"10.1007\/s10565-021-09690-1"},{"key":"9904_CR2","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.omtn.2021.10.023","volume":"26","author":"Z Chen","year":"2021","unstructured":"Chen Z, Zhong X, Xia M, Zhong J. The roles and mechanisms of the m6A reader protein YTHDF1 in tumor biology and human diseases. Mol Ther Nucleic Acids. 2021;26:1270\u20139. https:\/\/doi.org\/10.1016\/j.omtn.2021.10.023.","journal-title":"Mol Ther Nucleic Acids"},{"key":"9904_CR3","doi-asserted-by":"publisher","unstructured":"Chen, H., Yu, Y., Yang, M., Huang, H., Ma, S., Hu, J., . . . Li, L. (2022). YTHDF1 promotes breast cancer progression by facilitating FOXM1 translation in an m6A-dependent manner. Cell Biosci, 12(1), 19. https:\/\/doi.org\/10.1186\/s13578-022-00759-w","DOI":"10.1186\/s13578-022-00759-w"},{"key":"9904_CR4","doi-asserted-by":"publisher","unstructured":"Cheng, Y., Sun, F., Thornton, K., Jing, X., Dong, J., Yun, G., . . . Janz, S. (2022). FOXM1 regulates glycolysis and energy production in multiple myeloma. Oncogene, 41(32), 3899\u20133911. https:\/\/doi.org\/10.1038\/s41388-022-02398-4","DOI":"10.1038\/s41388-022-02398-4"},{"key":"9904_CR5","doi-asserted-by":"publisher","unstructured":"Cui, J., Shi, M., Xie, D., Wei, D., Jia, Z., Zheng, S., . . . Xie, K. (2014). FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Clin Cancer Res, 20(10), 2595\u20132606. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2407","DOI":"10.1158\/1078-0432.CCR-13-2407"},{"key":"9904_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1476-4598-12-152","volume":"12","author":"S Ganapathy-Kanniappan","year":"2013","unstructured":"Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152. https:\/\/doi.org\/10.1186\/1476-4598-12-152.","journal-title":"Mol Cancer"},{"issue":"1","key":"9904_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-017-0392-4","volume":"10","author":"Z Gu","year":"2017","unstructured":"Gu Z, Xia J, Xu H, Frech I, Tricot G, Zhan F. NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase. J Hematol Oncol. 2017;10(1):17. https:\/\/doi.org\/10.1186\/s13045-017-0392-4.","journal-title":"J Hematol Oncol"},{"key":"9904_CR8","doi-asserted-by":"publisher","unstructured":"Hua, Z., Wei, R., Guo, M., Lin, Z., Yu, X., Li, X., . . . Yang, Y. (2022). YTHDF2 promotes multiple myeloma cell proliferation via STAT5A\/MAP2K2\/p-ERK axis. Oncogene, 41(10), 1482\u20131491. https:\/\/doi.org\/10.1038\/s41388-022-02191-3","DOI":"10.1038\/s41388-022-02191-3"},{"key":"9904_CR9","doi-asserted-by":"publisher","unstructured":"Jian, D., Wang, Y., Jian, L., Tang, H., Rao, L., Chen, K., . . . Li, M. (2020). METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications. Theranostics, 10(20), 8939\u20138956. https:\/\/doi.org\/10.7150\/thno.45178","DOI":"10.7150\/thno.45178"},{"key":"9904_CR10","doi-asserted-by":"publisher","unstructured":"Jiang, F., Tang, X., Tang, C., Hua, Z., Ke, M., Wang, C., . . . Yang, Y. (2021). HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. J Hematol Oncol, 14(1), 54. https:\/\/doi.org\/10.1186\/s13045-021-01066-6","DOI":"10.1186\/s13045-021-01066-6"},{"key":"9904_CR11","doi-asserted-by":"publisher","unstructured":"Lan, T., Li, H., Zhang, D., Xu, L., Liu, H., Hao, X., . . . Wu, H. (2019). KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Mol Cancer, 18(1), 186. https:\/\/doi.org\/10.1186\/s12943-019-1106-z","DOI":"10.1186\/s12943-019-1106-z"},{"key":"9904_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12935-020-01309-5","volume":"20","author":"T Li","year":"2020","unstructured":"Li T, Gu M, Deng A, Qian C. Increased expression of YTHDF1 and HNRNPA2B1 as potent biomarkers for melanoma: a systematic analysis. Cancer Cell Int. 2020;20:239. https:\/\/doi.org\/10.1186\/s12935-020-01309-5.","journal-title":"Cancer Cell Int"},{"issue":"5","key":"9904_CR13","doi-asserted-by":"publisher","first-page":"11923","DOI":"10.1080\/21655979.2022.2065952","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, He L, Wang Y, Tan Y, Zhang F. N(6)-methyladenosine methyltransferase KIAA1429 elevates colorectal cancer aerobic glycolysis via HK2-dependent manner. Bioengineered. 2022;13(5):11923\u201332. https:\/\/doi.org\/10.1080\/21655979.2022.2065952.","journal-title":"Bioengineered"},{"key":"9904_CR14","doi-asserted-by":"publisher","unstructured":"Li, M., Chen, C., Wang, Q., Jiang, X., Tan, L., Huang, Y., . . . Zhang, Z. (2021). Glaucocalyxin A suppresses multiple myeloma progression in vitro and in vivo through inhibiting the activation of STAT3 signaling pathway. Cancer Cell Int, 21(1), 683. https:\/\/doi.org\/10.1186\/s12935-021-02375-z","DOI":"10.1186\/s12935-021-02375-z"},{"issue":"3","key":"9904_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2016;41(3):211\u20138. https:\/\/doi.org\/10.1016\/j.tibs.2015.12.001.","journal-title":"Trends Biochem Sci"},{"issue":"4","key":"9904_CR16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1309\/74R4-TB90-BUWH-27JX","volume":"121","author":"P Lin","year":"2004","unstructured":"Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121(4):482\u20138. https:\/\/doi.org\/10.1309\/74R4-TB90-BUWH-27JX.","journal-title":"Am J Clin Pathol"},{"key":"9904_CR17","doi-asserted-by":"publisher","unstructured":"Liu, R., Zhong, Y., Chen, R., Chu, C., Liu, G., Zhou, Y., . . . Liu, H. (2022). m(6)A reader hnRNPA2B1 drives multiple myeloma osteolytic bone disease. Theranostics, 12(18), 7760\u20137774. https:\/\/doi.org\/10.7150\/thno.76852","DOI":"10.7150\/thno.76852"},{"key":"9904_CR18","doi-asserted-by":"publisher","unstructured":"Liu, R., Miao, J., Jia, Y., Kong, G., Hong, F., Li, F., . . . He, A. (2023). N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1\/p21(cip1\/waf1)\/CDK2-Cyclin E1 axis-mediated cell cycle transition. Oncogene, 42(20), 1607\u20131619. https:\/\/doi.org\/10.1038\/s41388-023-02675-w","DOI":"10.1038\/s41388-023-02675-w"},{"issue":"2","key":"9904_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s11899-018-0443-0","volume":"13","author":"KB McCullough","year":"2018","unstructured":"McCullough KB, Hobbs MA, Abeykoon JP, Kapoor P. Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies. Curr Hematol Malig Rep. 2018;13(2):114\u201324. https:\/\/doi.org\/10.1007\/s11899-018-0443-0.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"9904_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7861\/clinmedicine.19-1-58","volume":"19","author":"C Medical Masterclass","year":"2019","unstructured":"Medical Masterclass C, Firth J. Haematology: multiple myeloma. Clin Med (Lond). 2019;19(1):58\u201360. https:\/\/doi.org\/10.7861\/clinmedicine.19-1-58.","journal-title":"Clin Med (Lond)"},{"issue":"1","key":"9904_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","volume":"9","author":"L Naymagon","year":"2016","unstructured":"Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9(1):52. https:\/\/doi.org\/10.1186\/s13045-016-0282-1.","journal-title":"J Hematol Oncol"},{"key":"9904_CR22","doi-asserted-by":"publisher","unstructured":"Qu, J., Hou, Y., Chen, Q., Chen, J., Li, Y., Zhang, E., . . . Cai, Z. (2022). RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-kappaB and MAPK signaling pathways. Oncogene, 41(3), 400\u2013413. https:\/\/doi.org\/10.1038\/s41388-021-02095-8","DOI":"10.1038\/s41388-021-02095-8"},{"issue":"Suppl 1(Suppl 1","key":"9904_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hon.2586","volume":"37","author":"SV Rajkumar","year":"2019","unstructured":"Rajkumar SV. Multiple myeloma: Every year a new standard? Hematol Oncol. 2019;37(Suppl 1(Suppl 1)):62\u20135. https:\/\/doi.org\/10.1002\/hon.2586.","journal-title":"Hematol Oncol"},{"key":"9904_CR24","doi-asserted-by":"publisher","unstructured":"Rawstron, A. C., Orfao, A., Beksac, M., Bezdickova, L., Brooimans, R. A., Bumbea, H., . . . European Myeloma, N. (2008). Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica, 93(3), 431\u2013438. https:\/\/doi.org\/10.3324\/haematol.11080","DOI":"10.3324\/haematol.11080"},{"issue":"7","key":"9904_CR25","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","volume":"169","author":"IA Roundtree","year":"2017","unstructured":"Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA Modifications in Gene Expression Regulation. Cell. 2017;169(7):1187\u2013200. https:\/\/doi.org\/10.1016\/j.cell.2017.05.045.","journal-title":"Cell"},{"key":"9904_CR26","doi-asserted-by":"publisher","unstructured":"Sanchez, W. Y., McGee, S. L., Connor, T., Mottram, B., Wilkinson, A., Whitehead, J. P., . . . Catley, L. (2013). Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib. Br J Cancer, 108(8), 1624\u20131633. https:\/\/doi.org\/10.1038\/bjc.2013.120","DOI":"10.1038\/bjc.2013.120"},{"issue":"6","key":"9904_CR27","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101\u20138. https:\/\/doi.org\/10.1038\/nprot.2008.73.","journal-title":"Nat Protoc"},{"key":"9904_CR28","doi-asserted-by":"publisher","unstructured":"Shi, H., Wang, X., Lu, Z., Zhao, B. S., Ma, H., Hsu, P. J., . . . He, C. (2017). YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res, 27(3), 315\u2013328. https:\/\/doi.org\/10.1038\/cr.2017.15","DOI":"10.1038\/cr.2017.15"},{"issue":"2","key":"9904_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21(2):141\u201362. https:\/\/doi.org\/10.1038\/s41573-021-00339-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"9904_CR30","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1007\/s00432-022-04426-y","volume":"149","author":"B Tang","year":"2023","unstructured":"Tang B, Li M, Xu Y, Li X. N(6)-methyladenosine (m(6)A) writer KIAA1429 accelerates gastric cancer oxaliplatin chemoresistance by targeting FOXM1. J Cancer Res Clin Oncol. 2023;149(8):5037\u201345. https:\/\/doi.org\/10.1007\/s00432-022-04426-y.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"9904_CR31","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41419-020-03071-y","volume":"11","author":"Q Wang","year":"2020","unstructured":"Wang Q, Guo X, Li L, Gao Z, Su X, Ji M, Liu J. N(6)-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1\/HK2 modification. Cell Death Dis. 2020;11(10):911. https:\/\/doi.org\/10.1038\/s41419-020-03071-y.","journal-title":"Cell Death Dis"},{"key":"9904_CR32","doi-asserted-by":"publisher","first-page":"918522","DOI":"10.3389\/fimmu.2022.918522","volume":"13","author":"T Wang","year":"2022","unstructured":"Wang T, Bai J, Zhang Y, Xue Y, Peng Q. N(6)-Methyladenosine regulator RBM15B acts as an independent prognostic biomarker and its clinical significance in uveal melanoma. Front Immunol. 2022;13:918522. https:\/\/doi.org\/10.3389\/fimmu.2022.918522.","journal-title":"Front Immunol"},{"issue":"2","key":"9904_CR33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/iub.2678","volume":"75","author":"J Wang","year":"2023","unstructured":"Wang J, Zuo Y, Lv C, Zhou M, Wan Y. N6-methyladenosine regulators are potential prognostic biomarkers for multiple myeloma. IUBMB Life. 2023;75(2):137\u201348. https:\/\/doi.org\/10.1002\/iub.2678.","journal-title":"IUBMB Life"},{"key":"9904_CR34","doi-asserted-by":"publisher","unstructured":"Wang, X., Zhao, B. S., Roundtree, I. A., Lu, Z., Han, D., Ma, H., . . . He, C. (2015). N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell, 161(6), 1388\u20131399. https:\/\/doi.org\/10.1016\/j.cell.2015.05.014","DOI":"10.1016\/j.cell.2015.05.014"},{"key":"9904_CR35","doi-asserted-by":"publisher","unstructured":"Xiao, W., Adhikari, S., Dahal, U., Chen, Y. S., Hao, Y. J., Sun, B. F., . . . Yang, Y. G. (2016). Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing. Mol Cell, 61(4), 507\u2013519. https:\/\/doi.org\/10.1016\/j.molcel.2016.01.012","DOI":"10.1016\/j.molcel.2016.01.012"},{"key":"9904_CR36","doi-asserted-by":"publisher","first-page":"101745","DOI":"10.1016\/j.tranon.2023.101745","volume":"36","author":"K Xu","year":"2023","unstructured":"Xu K, Dai X, Yue J. m(6)A methyltransferase KIAA1429 accelerates oral squamous cell carcinoma via regulating glycolysis and ferroptosis. Transl Oncol. 2023a;36:101745. https:\/\/doi.org\/10.1016\/j.tranon.2023.101745.","journal-title":"Transl Oncol"},{"key":"9904_CR37","doi-asserted-by":"publisher","unstructured":"Xu, A., Zhang, J., Zuo, L., Yan, H., Chen, L., Zhao, F., . . . Hu, Y. (2022). FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m(6)A-YTHDF2-dependent manner. Mol Ther, 30(3), 1104\u20131118. https:\/\/doi.org\/10.1016\/j.ymthe.2021.12.012","DOI":"10.1016\/j.ymthe.2021.12.012"},{"key":"9904_CR38","doi-asserted-by":"publisher","unstructured":"Xu, Z., Pei, C., Cheng, H., Song, K., Yang, J., Li, Y., . . . Meng, L. (2023b). Comprehensive analysis of FOXM1 immune infiltrates, m6a, glycolysis and ceRNA network in human hepatocellular carcinoma. Front Immunol, 14, 1138524. https:\/\/doi.org\/10.3389\/fimmu.2023.1138524","DOI":"10.3389\/fimmu.2023.1138524"},{"key":"9904_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12935-020-1118-1","volume":"20","author":"X Yang","year":"2020","unstructured":"Yang X, Huang H, Wang X, Liu H, Liu H, Lin Z. Knockdown of lncRNA SNHG16 suppresses multiple myeloma cell proliferation by sponging miR-342-3p. Cancer Cell Int. 2020;20:38. https:\/\/doi.org\/10.1186\/s12935-020-1118-1.","journal-title":"Cancer Cell Int"},{"key":"9904_CR40","doi-asserted-by":"publisher","unstructured":"Yang, D., Chang, S., Li, F., Ma, M., Yang, J., Lv, X., . . . Jia, C. (2021). m(6) A transferase KIAA1429-stabilized LINC00958 accelerates gastric cancer aerobic glycolysis through targeting GLUT1. IUBMB Life, 73(11), 1325\u20131333. https:\/\/doi.org\/10.1002\/iub.2545","DOI":"10.1002\/iub.2545"},{"key":"9904_CR41","doi-asserted-by":"publisher","unstructured":"Yao, X., Li, W., Li, L., Li, M., Zhao, Y., Fang, D., . . . Luo, Z. (2022). YTHDF1 upregulation mediates hypoxia-dependent breast cancer growth and metastasis through regulating PKM2 to affect glycolysis. Cell Death Dis, 13(3), 258. https:\/\/doi.org\/10.1038\/s41419-022-04711-1","DOI":"10.1038\/s41419-022-04711-1"},{"issue":"6","key":"9904_CR42","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.7150\/ijbs.64943","volume":"18","author":"T Yu","year":"2022","unstructured":"Yu T, Yao L, Yin H, Teng Y, Hong M, Wu Q. ALKBH5 Promotes Multiple Myeloma Tumorigenicity through inducing m(6)A-demethylation of SAV1 mRNA and Myeloma Stem Cell Phenotype. Int J Biol Sci. 2022;18(6):2235\u201348. https:\/\/doi.org\/10.7150\/ijbs.64943.","journal-title":"Int J Biol Sci"},{"key":"9904_CR43","doi-asserted-by":"publisher","unstructured":"Yue, Y., Liu, J., Cui, X., Cao, J., Luo, G., Zhang, Z., . . . Liu, J. (2018). VIRMA mediates preferential m(6)A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. Cell Discov, 4, 10. https:\/\/doi.org\/10.1038\/s41421-018-0019-0","DOI":"10.1038\/s41421-018-0019-0"},{"key":"9904_CR44","doi-asserted-by":"publisher","unstructured":"Zhang, C., Sun, Q., Zhang, X., Qin, N., Pu, Z., Gu, Y., . . . Shen, H. (2022). Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma. Cancer Commun (Lond), 42(7), 609\u2013626. https:\/\/doi.org\/10.1002\/cac2.12325","DOI":"10.1002\/cac2.12325"},{"key":"9904_CR45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.omtn.2019.11.022","volume":"19","author":"W Zhao","year":"2020","unstructured":"Zhao W, Qi X, Liu L, Ma S, Liu J, Wu J. Epigenetic Regulation of m(6)A Modifications in Human Cancer. Mol Ther Nucleic Acids. 2020;19:405\u201312. https:\/\/doi.org\/10.1016\/j.omtn.2019.11.022.","journal-title":"Mol Ther Nucleic Acids"},{"key":"9904_CR46","doi-asserted-by":"publisher","unstructured":"Zhao, Y., & Peng, H. (2022). The Role of N(6)-Methyladenosine (m(6)A) Methylation Modifications in Hematological Malignancies. Cancers (Basel), 14(2). https:\/\/doi.org\/10.3390\/cancers14020332","DOI":"10.3390\/cancers14020332"},{"key":"9904_CR47","doi-asserted-by":"publisher","unstructured":"Zhu, Z., Zhou, Y., Chen, Y., Zhou, Z., Liu, W., Zheng, L., . . . Li, Y. (2022). m(6)A Methyltransferase KIAA1429 Regulates the Cisplatin Sensitivity of Gastric Cancer Cells via Stabilizing FOXM1 mRNA. Cancers (Basel), 14(20). https:\/\/doi.org\/10.3390\/cancers14205025","DOI":"10.3390\/cancers14205025"},{"key":"9904_CR48","doi-asserted-by":"publisher","unstructured":"Zub, K. A., Sousa, M. M., Sarno, A., Sharma, A., Demirovic, A., Rao, S., . . . Slupphaug, G. (2015). Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells. PLoS One, 10(3), e0119857. https:\/\/doi.org\/10.1371\/journal.pone.0119857","DOI":"10.1371\/journal.pone.0119857"}],"container-title":["Cell Biology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-024-09904-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10565-024-09904-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-024-09904-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:32:14Z","timestamp":1735867934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10565-024-09904-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9904"],"URL":"https:\/\/doi.org\/10.1007\/s10565-024-09904-2","relation":{},"ISSN":["1573-6822"],"issn-type":[{"value":"1573-6822","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"14 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent and experiments were conducted following the Helsinki Declaration and its amendments. This study was approved by the Ethics Committee of Beijing Chao-Yang Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}